Maravai -7.5% led the nucleic-acid rung lower with the China CDMO names, while the bioprocessing-instrument chokepoint held — Mettler-Toledo +2.2%.

Mettler-Toledo (MTD) led the pharma-supply basket Tuesday, up 2.2% to $1,598.03, with Repligen (RGEN) +1.7% to $175.42 and West Pharmaceutical (WST) +1.1% to $371.82 — the precision-instrument and bioprocessing-consumable names that sit on the least-substitutable rung of the drug-manufacturing chain. The gains were modest and idiosyncratic rather than a sector move; on a day the broad tape finished slightly lower, the analytical-instruments and fill-finish suppliers simply held while the nucleic-acid and China-exposed rungs sold off. Danaher (DHR) +0.7% to $222.84 and Corning (GLW) +0.9% to $148.54 rounded out the firm side.

The laggard was Maravai LifeSciences (MRVI), down 7.5% to $6.53 on heavy volume, with no company-specific catalyst in the tape — a continued derating of the mRNA-and-nucleic-acid production rung, where Maravai's CleanCap capping reagents are the franchise. The weakness clustered with the China CDMO names that carry the clearest policy overhang: WuXi Biologics (WXIBF) -3.4% to $6.52 and WuXi AppTec (WUXAY) -2.4% to $26.19. Generic and specialty makers slipped too — Amphastar (AMPH) -2.7% to $26.05, Amneal (AMRX) -2.3% to $19.57. This is the outsourced-manufacturing chokepoint repricing on legislative risk rather than fundamentals: own the capacity, and the question is whether US policy lets you keep selling into it.

The rest of the supply chain was quiet-to-mixed. On the containment-and-delivery rung — the vials, syringes and stoppers that gate every injectable — Stevanato (STVN) was roughly flat at $19.26 and West firmed, while the European bioprocessing names were little changed (Sartorius ADR, SOAGY, -0.4% to $56.40). The large-cap drug makers that pull demand through the whole chain were soft: Eli Lilly (LLY) -1.4% to $1,166.51 and Novo Nordisk (NVO) -1.3% to $38.06, the GLP-1 duopoly whose volume underwrites much of the fill-finish buildout. The read is a market separating the picks-and-shovels suppliers from the policy-exposed manufacturing names.

The calendar turns on earnings and one hard policy date. West Pharmaceutical reports Q3 on October 22 — the clearest read on injectable-components demand — followed by Charles River (Q3, ~November 5) on the preclinical-services rung. The structural catalyst for the names that fell Tuesday is December 18, the statutory deadline for the OMB to publish its initial BIOSECURE list of biotechnology "companies of concern," the designation that would formalize the China-CDMO overhang now weighing on the WuXi complex.